Investors

News Release Details

Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022

May 3, 2022 at 8:00 AM EDT

SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.  

The Company’s management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667. Following the live webcast, an archived version of the call will be available on the website.

Tuesday May 10 @ 4:30 pm ET

Domestic: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13728852
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com


Primary Logo

Source: Opiant Pharmaceuticals, Inc.